- CH₣1.45bn
- CH₣1.53bn
- €391.95m
Brief: Polypeptide Group Provisional Interim Result Of The Public Tender Offer Of Samsung Biologics Co
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Samsung Biologics to launch takeover bid for PolyPeptide in September (updated)
Samsung Peptide to launch takeover bid for Swiss PolyPeptide
Brief: Polypeptide Board Recommends Shareholders Accept Samsung Offer
Brief: Samsung Peptide Launches Tender Offer For Polypeptide
Berenberg cuts PolyPeptide as tender offer, share gains limit upside
Europe Research Roundup: Hemnet, Polypeptide Group, UMG
Switzerland's PolyPeptide H1 revenue rises on stronger metabolic therapeutics demand
Brief: PolyPeptide Group H1 Revenue EUR 236.628 Million
Deals of the day-Mergers and acquisitions
PolyPeptide rises after Samsung Biologics launches bid
Swiss stocks - Factors to watch on July 20
Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide (updated)
Samsung Biologics to launch $1.8 billion all cash bid for PolyPeptide
Brief: Samsung Biologics To Acquire Polypeptide Group AG For 2.7 Trln Won
Brief: Polypeptide Updates FY 2026 Guidance To 25-30% Revenue Growth, High-Teens Ebitda Margin
Brief: Samsung Biologics To Buy Polypeptide For Chf 44.31 Per Share, Equity Value CHF 1.46 Billion